|
KMID : 0191120180330010007
|
|
Journal of Korean Medical Science
2018 Volume.33 No. 1 p.7 ~ p.7
|
|
|
Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report
|
|
Park Cheol-Kyu
Hur Jae-Young
Choi Chang-Min
Kim Tae-Ok
Cho Hyun-Ju
Shin Hong-Joon
Lim Jung-Hwan
Choi Yoo-Duk
Kim Young-Chul
Oh In-Jae
|
|
|
Abstract
|
|
|
|
Human epidermal growth factor receptor 2 (HER2) mutation in non-small cell lung cancer (NSCLC) is an oncogenic driver that possibly becomes a druggable target to HER2-targeted therapy. The benefit of HER2-targeted therapy is much less defined especially in eastern populations. We provide evidence of clinical benefit of afatinib in a 50-year-old Asian woman with HER2-mutant NSCLC who previously failed cytotoxic chemotherapy and gefitinib treatment. Next-generation sequencing of the tumor tissue revealed a HER2 exon 20 mutation (c.2437A>G), which has never been reported. The patient was treated with afatinib for more than four months. She showed rapid radiologic response within a month, and maintained stable state until the last dose of afatinib.
|
|
|
KEYWORD
|
|
|
HER2 mutation, Non-small Cell Lung Cancer, Afatinib
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|